Ads
related to: breast cancer treatment drugs herceptin- Metastatic Breast Cancer
Visit For Info On A Metastatic
Breast Cancer Rx Treatment Option.
- mBC Patient Stories
Find Inspirational Stories Of Women
With Metastatic Breast Cancer
- Treatment Option
Learn About An Rx Treatment Option
For Metastatic Breast Cancer.
- Tips On Living With mBC
Tips On Coping, Motherhood,
Relationships & Nutrition
- Metastatic Breast Cancer
Search results
Results From The WOW.Com Content Network
Trastuzumab. Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [20] [17] [21] [22] It is specifically used for cancer that is HER2 receptor positive. [20] It may be used by itself or together with other chemotherapy medication. [20]
Clinical trial number NCT01566721 for "A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)" at ClinicalTrials.gov
Slamon is a physician scientist at UCLA Medical Center (Los Angeles), where he has developed the experimental drug Herceptin, which he believes will become a treatment for breast cancer. However, when the drug company stops funding the research, philanthropists, including Lilly Tartikoff (Angie Harmon) and Ronald Perelman help him continue drug ...
In the United States, trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.
July 29, 2024 at 10:27 AM. A life-extending drug for incurable breast cancer will not be made available on the health service in England after its manufacturers and the NHS spending watchdog ...
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan ). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and safety as IV ...
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab. [3]
Ads
related to: breast cancer treatment drugs herceptin